
By Mariam Sunny and Michael Erman
(Reuters) -Merck said on Monday it expects a commercial opportunity exceeding $5 billion from Cidara Therapeutics' experimental flu drug, and does not anticipate it to require a review by the U.S. CDC's vaccine advisory panel before launch.
The U.S. drugmaker announced a nearly $9.2 billion deal last week to acquire Cidara, aiming to gain access to its long-acting antiviral, CD388, currently in late-stage trial.
CD388 is not a vaccine and is designed to be effective regardless of a person's immune status and could offer single-dose, universal protection against all flu strains.
Vaccine policy in the United States has been undergoing a shift under Health Secretary Robert F. Kennedy Jr., a longtime vaccine skeptic, who has revamped the Centers for Disease Control and Prevention's panel of outside advisers and prompted the ouster of its director.
"I would not say that our view of what is happening around vaccinations has in any way affected either our view of vaccinations or what drove us to this (drug)," Merck CEO Robert Davis said during a call with analysts.
Merck expects about 110 million Americans to be eligible to receive CD388, including 85 million considered at high risk for influenza. It plans to manufacture the drug long-term at one of its U.S. facilities.
The company said it expects Cidara's acquisition to reduce earnings by about 30 cents per share over the first 12 months from the deal's closing, reflecting investments to advance CD388 and the assumed cost of financing.
The deal is expected to close in the first quarter of 2026.
(Reporting by Mariam Sunny in Bengaluru and Michael Erman in New Jersey; Editing by Shilpi Majumdar)
LATEST POSTS
- 1
Instructions to Warmly greet Certainty and Appeal - 2
Fetterman says he's back home after a fall put the Pennsylvania senator in the hospital - 3
Timex Gives Its Classic Affordable Field Watch a Tactical, Milspec Makeover - 4
New science points to 4 distinct types of autism - 5
Embrace Effortlessness: Moderation and Cleaning up Tips
Vote in favor of Your #1 Home Exercise Gear: Execution and Comfort Matter
Moon fever hits DC as Artemis 2 rocket 'candle' lights up Washington Monument just 1 month before launch (photos)
'Euphoria' releases Season 3 trailer, premiere date: Watch Rue and Laurie finally face off
Spain breaks jobs record with 22 million Social Security contributors
French high-speed train slams into truck, killing TGV driver
In blow to Lula, Brazil Congress revives controversial environmental bill
White House responds to Sabrina Carpenter after pop star slams 'evil' ICE video using her song
UN torture cm'tee report flags Israel for allegedly mistreating journalists, detainees, ex-MAG
'All's Fair,' Ryan Murphy's new show starring Kim Kardashian, hit with scathing reviews: 'A girlboss fever dream'










